Despite the broad market sell-off, the IPO market is on pace for the most active October since 2014. And the average return for this month's deals is an impressive 16.1%. In October, 19 companies have raised $4.4 billion, with up to three more listings by...read more
Four IPOs raised $767 million. Even as the broader IPO market traded off, all four companies this week were positive and three popped 40% or more. Big data software provider Elastic (ESTC) priced well above its range and flew up 94%. With...read more
Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, raised $238 million by offering 12.5 million shares at $19, above the range of $15 to $17. Guardant Health plans to list on the Nasdaq under the symbol GH. J.P. Morgan and BofA...read more
October's winners & losers: Growth IPOs still flying high
Despite the market sell-off, the October IPO market was relatively active with 22 deals, and ...read more
October IPOs soar 16% even as markets sink
Despite the broad market sell-off, the IPO market is on pace for the most active October since 2014. And the average return for this month's deals is an impressive 16.1%. In October, 19 companies have raised $4.4 billion, with up to three more listings by...read more
US IPO Weekly Recap: US tech IPOs on a tear as Elastic bounds 94%
Four IPOs raised $767 million. Even as the broader IPO market traded off, all four companies this week were positive and three popped 40% or more. Big data software provider Elastic (ESTC) priced well above its range and flew up 94%. With...read more
Unguarded optimism: blood-based cancer test maker Guardant Health prices $238 million IPO at $19, above the range
Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, raised $238 million by offering 12.5 million shares at $19, above the range of $15 to $17. Guardant Health plans to list on the Nasdaq under the symbol GH. J.P. Morgan and BofA...read more